… Recent advances seen in immunotherapies targeting metastatic melanoma and other cancers
show the extraordinary capacity of redirecting the immune system and warrant advancing …

… phase study with autologous ex-vivo expanded DCs pulsed with allogeneic tumor cell lysate
in patients with metastatic melanoma to … All patients received 1-3 × 10 6 tumor lysate-pulsed …

… -specific immune response, which de facto constitutes an anti-cancer vaccine. Exploiting …
of the autologous tumor lysate pulsed DC-CIK treatment in CRC patients (NCT02202928, …

… -metastatic prostate cancer patients were treated with a Tn-MUC1 glycopeptide-dendritic cell
(DC) vaccine in a phase I/II clinical trial [18… squamous cell cancer and D5 melanoma mouse …

… -tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide
(Cy) elicited neoantigen-specific T cells and … In phase II metastatic melanoma study, …

… -derived natural killer cells and dendritic cells as well as … In a study, ACT with tumor
lysate-pulsed DC–CIK cells significantly … T cells are also useful in renal cell cancer, colorectal …

… CMS1 exhibits a high infiltration of innate immune cells [dendritic cells (DCs)… Vaccines
for colorectal cancer … for CRC vaccines include CEA, mucin 1 (MUC-1), and melanoma-associated …

… CAR T cells in a patient with advanced colorectal cancer, low … used in GC vaccines include
HER2, melanoma-associated … In a phase I/II study, 2-week DC vaccination combined with …

… Immunotherapy with tumor lysate-pulsed dendritic cells (DCs… subcutaneous injection
of LM8 murine osteosarcoma cells) … in patients with melanoma and renal cell carcinoma (8,9,13). …

… was also correlated with the extent of DC infiltration in patients with melanoma [33]. These
… using copolymers as adjuvants combined with TAAs for MC38 colorectal cancer treatment. …